Chicaíza-Becerra, Liliana <br/><br/>
ErbB2+ metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country.  [electronic resource] 

 -  Revista de salud publica (Bogota, Colombia)   
 - 270-80 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>2539-3596 
<br/><br/><label>Standard No.: </label>10.15446/rsap.v16n2.31690  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antimetabolites, Antineoplastic--economics<br/>Antineoplastic Combined Chemotherapy Protocols--economics<br/>Breast Neoplasms--drug therapy<br/>Capecitabine--administration & dosage<br/>Carcinoma, Ductal, Breast--drug therapy<br/>Colombia<br/>Cost-Benefit Analysis<br/>Developing Countries<br/>Disease Progression<br/>Disease-Free Survival<br/>Drug Resistance, Neoplasm<br/>Female<br/>Health Expenditures<br/>Humans<br/>Insurance, Health, Reimbursement<br/>Lapatinib<br/>Markov Chains<br/>Middle Aged<br/>Prescription Fees<br/>Quinazolines--administration & dosage<br/>Receptor, ErbB-2--analysis<br/>Taxoids--administration & dosage<br/>Trastuzumab--administration & dosage<br/>Vinblastine--administration & dosage<br/>Vinorelbine